Prospera Financial Services Inc Increases Stake in CVS Health Co. (NYSE:CVS)

Prospera Financial Services Inc boosted its position in shares of CVS Health Co. (NYSE:CVS) by 5.8% during the 3rd quarter, according to its most recent 13F filing with the SEC. The fund owned 34,555 shares of the pharmacy operator’s stock after purchasing an additional 1,908 shares during the quarter. Prospera Financial Services Inc’s holdings in CVS Health were worth $2,174,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of CVS. Bessemer Group Inc. boosted its holdings in shares of CVS Health by 55.5% during the 1st quarter. Bessemer Group Inc. now owns 73,343 shares of the pharmacy operator’s stock valued at $5,849,000 after acquiring an additional 26,173 shares during the last quarter. Crewe Advisors LLC purchased a new stake in shares of CVS Health during the 1st quarter valued at about $40,000. EntryPoint Capital LLC boosted its holdings in shares of CVS Health by 127.5% during the 1st quarter. EntryPoint Capital LLC now owns 1,397 shares of the pharmacy operator’s stock valued at $111,000 after acquiring an additional 783 shares during the last quarter. CreativeOne Wealth LLC boosted its holdings in shares of CVS Health by 21.8% during the 1st quarter. CreativeOne Wealth LLC now owns 9,414 shares of the pharmacy operator’s stock valued at $750,000 after acquiring an additional 1,688 shares during the last quarter. Finally, Axxcess Wealth Management LLC boosted its holdings in shares of CVS Health by 24.0% during the 1st quarter. Axxcess Wealth Management LLC now owns 26,996 shares of the pharmacy operator’s stock valued at $2,153,000 after acquiring an additional 5,229 shares during the last quarter. 80.66% of the stock is owned by hedge funds and other institutional investors.

CVS Health Stock Up 1.9 %

Shares of CVS stock opened at $56.83 on Thursday. The stock has a market cap of $71.52 billion, a P/E ratio of 14.42, a PEG ratio of 0.92 and a beta of 0.55. CVS Health Co. has a 52 week low of $52.71 and a 52 week high of $83.25. The company has a quick ratio of 0.59, a current ratio of 0.80 and a debt-to-equity ratio of 0.80. The company’s fifty day simple moving average is $59.18 and its two-hundred day simple moving average is $58.61.

CVS Health (NYSE:CVS) last announced its quarterly earnings results on Wednesday, November 6th. The pharmacy operator reported $1.09 EPS for the quarter, topping the consensus estimate of $1.08 by $0.01. The business had revenue of $95.43 billion for the quarter, compared to analysts’ expectations of $92.72 billion. CVS Health had a net margin of 1.36% and a return on equity of 10.72%. The business’s quarterly revenue was up 6.3% compared to the same quarter last year. During the same quarter in the previous year, the company earned $2.21 EPS. Analysts predict that CVS Health Co. will post 5.48 EPS for the current fiscal year.

CVS Health Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Friday, November 1st. Stockholders of record on Monday, October 21st were given a dividend of $0.665 per share. This represents a $2.66 annualized dividend and a dividend yield of 4.68%. The ex-dividend date was Monday, October 21st. CVS Health’s dividend payout ratio is 67.51%.

Analysts Set New Price Targets

CVS has been the topic of several recent research reports. Barclays lowered their price objective on shares of CVS Health from $75.00 to $71.00 and set an “overweight” rating on the stock in a research note on Thursday, November 7th. Cantor Fitzgerald reiterated a “neutral” rating and set a $62.00 price target on shares of CVS Health in a research note on Tuesday, October 1st. Royal Bank of Canada reduced their price objective on CVS Health from $68.00 to $58.00 and set an “outperform” rating for the company in a research note on Friday, November 15th. Evercore ISI lifted their target price on CVS Health from $62.00 to $75.00 and gave the company an “outperform” rating in a research report on Tuesday, October 8th. Finally, Deutsche Bank Aktiengesellschaft reduced their price target on CVS Health from $64.00 to $63.00 and set a “hold” rating for the company in a research report on Friday, August 9th. One research analyst has rated the stock with a sell rating, seven have assigned a hold rating and thirteen have issued a buy rating to the company. Based on data from MarketBeat, CVS Health has a consensus rating of “Moderate Buy” and an average target price of $72.28.

About CVS Health

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.